19 Nov 2026 · 3 min read
Bruce Booth says AI makes pharma R&D worse first. a16z disagrees. I side with Booth.
Bruce Booth expects AI to hurt pharma R&D productivity for three to five years. a16z disagrees. Why crowded targets favor Booth.
Insights / Industry
Field notes on Healthcare Venture Capital — who's deploying, what's getting funded, and where the late-cycle dynamics are pinching.
5 posts in Venture Capital
19 Nov 2026 · 3 min read
Bruce Booth expects AI to hurt pharma R&D productivity for three to five years. a16z disagrees. Why crowded targets favor Booth.
22 Oct 2026 · 2 min read
OpenAI bought Orchestra Bio six months after Anthropic paid a reported $400M for Coefficient Bio. Both deals were narrow, and for many AI research tool startups the frontier lab may show up as a competitor before it shows up as an acquirer.
13 Oct 2026 · 1 min read
Rock Health counts over $140B raised by US digital health startups since 2011, yet the last IPO was HeartFlow in August 2025. Why I now ask the exit question much earlier.
12 May 2026 · 4 min read
Isomorphic Labs is in advanced talks to raise more than $2B, and I'm of two minds about it. The capital is welcome, but the deeper question is whether tech boards will stay patient through a decade of clinical iteration — and whether anyone is funding the downstream bottleneck that more AI-generated candidates will only tighten.
27 Jun 2024 · 1 min read
Despite the challenging fundraising environment, we are witnessing significant investments in AI-enabled drug discovery and development. Formation Bio's nearly $400M Series D and Xaira Therapeutics' emergence from stealth mode signal intensifying competition among major VC funds to lead in AI-powered biotech innovations.